NCT02114775View on ClinicalTrials.gov

Growth Hormone or Sildenafil as Therapies for Fatigue in Mild- Traumatic-brain-injury (MTBI)

PHASE1CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

December 12, 2014

Primary Completion Date

November 10, 2017

Study Completion Date

November 10, 2017

Conditions
Traumatic Brain Injury
Interventions
DRUG

Growth Hormone

0.4 mg/day injected subcutaneously for one month then increased to 0.6 mg/day for two months during crossover phase. After crossover phase, 0.6 mg/day for six months

DRUG

Sildenafil

50 mg by mouth daily

DRUG

Placebo

Placebo either injected (GH group) or orally (sildenafil group) daily for three months during crossover phase of the study

Trial Locations (1)

77555

University of Texas Medical Branch, Galveston

All Listed Sponsors
lead

The University of Texas Medical Branch, Galveston

OTHER

NCT02114775 - Growth Hormone or Sildenafil as Therapies for Fatigue in Mild- Traumatic-brain-injury (MTBI) | Biotech Hunter | Biotech Hunter